SCHEMBL13625970

SCHEMBL13625970

CCC(=O)[C@@H](NC(C)=O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
NFKB1 P19838 1/20 0.34
PTGS2 P35354 1/20 0.34
THPO P40225 1/20 0.34
RECQL P46063 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
PLA2G2A P14555 1/20 0.33
PLA2G5 P39877 1/20 0.33
ADAM17 P78536 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486076 1.00 ALDH1A1 (0.38) ALDH1A1DPP4DPP8DPP9MEN1
SCHEMBL13545139 0.84 ALDH1A1 (0.36) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL12175329 0.78 CTSK (0.36) SMN1; SMN2MAPTPLA2G2APLA2G5ACACB
SCHEMBL13048834 0.78 CTSK (0.36) SMN1; SMN2MAPTPLA2G2APLA2G5ACACB
SCHEMBL10177450 0.78 CTSK (0.36) SMN1; SMN2MAPTPLA2G2APLA2G5ACACB
SCHEMBL12505733 0.78 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL17902951 0.77 FNTA (0.33)
SCHEMBL11782126 0.76 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KDM4EMAPTTHRB
SCHEMBL10140506 0.76 SMN1; SMN2 (0.32) ALDH1A1DPP4SMN1; SMN2TDP1PLA2G2A
SCHEMBL12824659 0.76 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-01-05 US disclosed
WO-2009136352-A1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND, LTD. (IE) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR1A, HTR2C ALDH1A1 3128/4885DPP4 2741/4885DPP8 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.